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EphA2 is a receptor tyrosine kinase (RTK) that triggers keratinocyte differentiation upon activation and
subsequent downregulation by ephrin-A1 ligand. The objective of this study was to determine whether the
EphA2/ephrin-A1 signaling axis was altered in psoriasis, an inflammatory skin condition in which keratinocyte
differentiation is abnormal. Microarray analysis of skin biopsies from psoriasis patients revealed increased mRNA
transcripts for several members of this RTK family in plaques, including the EphA1, EphA2, and EphA4 subtypes
prominently expressed by keratinocytes. Of these, EphA2 showed the greatest upregulation, a finding that was
confirmed by quantitative reverse-transcriptase–PCR, immunohistochemistry (IHC), and ELISA. In contrast,
psoriatic lesions exhibited reduced ephrin-A ligand immunoreactivity. Exposure of primary keratinocytes induced
to differentiate in high calcium or a three-dimensional (3D) raft culture of human epidermis to a combination of
growth factors and cytokines elevated in psoriasis increased EphA2 mRNA and protein expression while inducing
S100A7 and disrupting differentiation. Pharmacological delivery of a soluble ephrin-A1 peptidomimetic ligand led
to a reduction in EphA2 expression and ameliorated proliferation and differentiation in raft cultures exposed to
EGF and IL-1a. These findings suggest that ephrin-A1-mediated downregulation of EphA2 supports keratinocyte
differentiation in the context of cytokine perturbation.
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INTRODUCTION
Erythropoietin-producing hepatocellular (Eph) receptors make
up the largest family of receptor tyrosine kinases (RTKs) in
humans (Eph Nomenclature Committee, 1997; Pasquale,
2005). These RTKs are grouped into EphA (1–8/10) and EphB
(1–4/6) subtypes based on sequence homology and binding
to glycosylphosphatidylinositol-linked ephrin-A (1–5) or trans-
membrane ephrin-B (1–3) ligands that are anchored on
neighboring cells. Eph/ephrin signaling complexes mediate
developmental patterning events in embryonic tissues and the
establishment of tumor boundaries in cancers (Lackmann and
Boyd, 2008; Batlle and Wilkinson, 2012). This cell–cell
communication pathway has also been implicated in main-
taining homeostasis of adult epithelial tissues, including the
epidermis, but relatively little is known about their roles in
skin disease (Miao and Wang, 2009; Lin et al., 2012).
The mRNA transcripts for all members of the Eph/ephrin
family can be detected in human skin, but a more limited
repertoire (i.e., receptors: EphA1/2/4 and EphB3/B4; ligands:
ephrin-A1/3/4 and ephrin-B1–3) is likely present in cultured
keratinocytes (Hafner et al., 2006; Walsh and Blumenberg,
2011). A number of cellular processes can be modulated by
Eph/ephrin signaling in keratinocytes, including proliferation,
adhesion, migration, survival, and differentiation (Guo et al.,
2006; Yamada et al., 2008; Zhang et al., 2008; Egawa et al.,
2009; Genander et al., 2010; Lin et al., 2010; Walsh and
Blumenberg, 2011, 2012; Kaplan et al., 2012). For example,
ligand targeting of EphA2 with a soluble, recombinant ephrin-
A1-Fc (EfnA1-Fc) protein triggers receptor activation and
subsequent downregulation, leading to an increase in
desmosome-mediated adhesion and keratinocyte differen-
tiation (Lin et al., 2010). Although dispensable for normal
cell cycle exit in culture, EphA2 can be harnessed by ephrins
to negatively regulate keratinocyte proliferation (Guo et al.,
2006; Genander et al., 2010; Walsh and Blumenberg, 2011).
Ligand-independent functions for EphA2 have also been
described in tumor cells, where it is frequently overexpressed
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(Beauchamp and Debinski, 2012; Miao and Wang, 2012).
For example, EphA2 promotes glioma cell invasion in the
absence of ligand, whereas ephrin-A1 targets this receptor to
inhibit cell migration, including in corneal epithelial cells (Miao
et al., 2009; Kaplan et al., 2012). These findings raise the
intriguing possibility that pharmacological approaches directed
at EphA2 may dampen keratinocyte proliferation and bolster
differentiation in pathological conditions.
Psoriasis is a common inflammatory skin disorder that has a
critical immunological component involving multiple T-cell
subtypes, particularly of the T helper type 1 and T helper type
17 lineage, and is further characterized by striking changes in the
epidermal compartment, which include abnormal keratinocyte
proliferation and differentiation (Tschachler, 2007; Elder et al.,
2010; Di Meglio et al., 2011; Guttman-Yassky et al., 2011).
Moreover, keratinocytes are key participants in the inflammatory
cascade; they not only respond to the cytokine milieu in lesions
but also secrete their own immunomodulatory, chemotactic, and
innate host defense factors (Swamy et al., 2010; Gutowska-
Owsiak and Ogg, 2012). Global gene expression studies of
psoriatic lesions indicate that the expression of a number of Eph
RTKs and ephrins may be altered in psoriasis (Kulski et al., 2005;
Piruzian et al., 2009; Jabbari et al., 2012).
In view of these observations, we analyzed EPH/EFN gene
expression levels in a large cohort of patients with psoriasis
and validated changes for epidermal components within the
A subclass. By focusing on the elevation of EphA2 in psoriatic
lesions, we examined its regulation by growth factors and
proinflammatory cytokines using primary human epidermal
keratinocytes and a three-dimensional (3D) organotypic raft
model of the human epidermis. Finally, we tested the
possibility of delivering soluble EfnA1-Fc to keratinocytes
exposed to cytokines as a means to target EphA2 for activation
and downregulation in order to normalize differentiation.
RESULTS
EphA2 is downregulated during keratinocyte differentiation
We previously showed that EphA2 is activated by ephrin-A
ligand in a contact-dependent manner in keratinocytes and
that delivery of additional, soluble ephrin-A1 peptide mimetic
(i.e., EfnA1-Fc) enhances EphA2 activation and subsequent
receptor downregulation, leading to increased differentiation
(Lin et al., 2010). Although primary keratinocytes coexpress
EphA2 and ephrin-A1, we were unable to detect endogenous
expression of the related ephrin-A3 in these primary cultures
by western blot analysis (Supplementary Figure S1 online).
Moreover, increasing levels of membrane-associated ephrin-
A1, but not ephrin-A3, by ectopic overexpression efficiently
reduced EphA2 levels, suggesting that ephrin-A1 is a major
ligand for the activation and downregulation of this receptor
subtype in keratinocytes.
These findings led us to determine whether the normal
expression pattern of EphA2 changes during keratinocyte
differentiation in vitro. Distinct from other epidermal EphA
subtypes, EphA2 mRNA transcripts were markedly reduced
in neonatal foreskin keratinocytes undergoing differentiation
in response to elevated calcium (1.2 mM Ca2þ ) or in a 3D
organotypic raft model of the human epidermis (Figure 1a).
EphA2 along with EphA1 and ephrin-A1 were readily detect-
able by western blotting in undifferentiated keratinocytes
maintained in low (0.03 mM) Ca2þ (Figure 1b). Raising the
extracellular Ca2þ levels (1.2 mM) reduced EphA2, whereas
EphA1 and ephrin-A1 remained abundantly expressed, and
EphA4 was markedly upregulated upon induction of differ-
entiation as reflected by increased levels of structural proteins
present in the suprabasal layers (desmoglein 1, desmocollin 1,
keratin 10 (K10), and loricrin). Furthermore, EphA2 was
downregulated in epidermal raft cultures and even further
reduced in extracts prepared from foreskin tissue, whereas
EphA1 and EphA4 remained high (Figure 1c). Collectively,
these results suggest that the relative abundance of ephrin-A1
ligand and the state of keratinocyte differentiation affect
EphA2 expression levels in the epidermis.
EphA2 is increased in psoriatic epidermis
Microarray studies indicate that EphA2 is increased in psor-
iatic plaques where keratinocyte differentiation is impaired
(Kulski et al., 2005; Piruzian et al., 2009; Jabbari et al., 2012).
To examine EPH/EFN gene expression in psoriasis in more
detail, we first used a previously generated microarray data set
to analyze the skin of normal individuals (n¼64) compared
with paired biopsies obtained from uninvolved and lesional
areas of patients with psoriasis (n¼58) (Gudjonsson et al.,
2010a). A number of changes for these receptors and ligands
were revealed when comparing psoriatic plaques (PP) with
either nonlesional (PN) or normal (NN) controls (Figure 2a and
Supplementary Figure S2 and Supplementary Table S1 online).
Of the 14 Eph RTK family members, EPHA2 showed the
greatest increase in psoriatic plaques. Interestingly, the other
EphA subtypes expressed by keratinocytes (EPHA1 and
EPHA4) were also elevated in lesional skin. In contrast, the
mRNA transcripts for epidermal ephrin-A ligands (EFNA1,
EFNA3, and EFNA4) were decreased in psoriatic plaques,
particularly when compared with uninvolved patient skin.
Similar to epidermal ephrin-A ligands, EFNB2 and EFNB3
were reduced in lesional skin. Several EphB family members
were also altered in psoriatic plaques, the most striking being
an increase in EPHB2, as well as a decrease in EPHB1 and
EPHB6; these particular receptor subtypes happen not to be
concentrated in keratinocytes (Walsh and Blumenberg, 2011).
Given the prominent changes observed in the epidermal
components of the EphA/ephrin-A subfamily, we focused our
analysis on EphA1, EphA2, and EphA4, as well as on ephrin-
A1 and ephrin-A3, as these two ligands differ in their ability to
downregulate EphA2 (Supplementary Figure S1 online) and
have somewhat distinct signaling functions in keratinocytes
(Walsh and Blumenberg, 2011). To validate the microarray
differences, we performed real-time, quantitative reverse-
transcriptase–PCR using skin biopsies from 7 normal controls
and 10 patients from uninvolved or lesional regions (Figure 2b).
The increase in EphA2 mRNA transcripts in psoriatic plaques
was confirmed when compared with uninvolved or normal
skin (PP vs. PN¼ 1.64 fold change (FC); PP vs. NN¼2.52 FC).
EphA1 (PP vs. NN¼ 1.98 FC) and EphA4 (PP vs. NN¼1.77
FC) mRNA levels were also higher in plaques, but only when
compared with healthy controls. Finally, ephrin-A1 and
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ephrin-A3 mRNA levels tended to be lower in psoriatic
plaques compared with uninvolved areas of patient skin, but
this only achieved statistical significance in the latter case (PP
vs. PN: EFNA1 0.51 FC; Po0.07; EFNA3 0.30 FC; Po0.05).
To determine whether EphA2 expression was increased at
the protein level in the epidermis of psoriatic plaques, we
performed immunohistochemical (IHC) analysis for this RTK
along with ephrin-A1 and ephrin-A3 (Figure 2c and d).
Although detectable at the periphery of keratinocytes from
normal individuals and uninvolved patient skin, particularly in
the suprabasal layers, EphA2 immunoreactivity was markedly
increased in psoriatic lesions. An ELISA for EphA2 confirmed
its increased expression in plaques (Figure 2e). Ephrin-A1,
which is normally concentrated in basal keratinocytes (Guo
et al., 2006), was reduced in the basal layer and occasionally
found in the suprabasal layers of psoriatic plaques. While
ephrin-A3 immunoreactivity was reduced in the basal layer
of psoriatic plaques, this ligand was also decreased in non-
lesional epidermis where EphA2 levels remain low. These
observations suggested that the EphA2/ephrin-A1 signaling axis
is disrupted in psoriatic epidermis, leading us to focus on this
particular receptor–ligand pair in keratinocyte culture models.
EphA2 is elevated by EGF and proinflammatory cytokines in
differentiated keratinocytes
EphA2 levels are increased when the EGFR–Erk1/2 signaling
pathway is activated in cancer cell lines (Macrae et al., 2005;
Larsen et al., 2007). Interestingly, several EGFR ligands are
present at high levels in psoriatic plaques and have been
shown to act in concert with IL-1a on keratinocytes to regulate
antimicrobial defense proteins elevated in this inflammatory
disease, including S100A7/psoriasin (Madsen et al., 1991;
Mee et al., 2007; Johnston et al., 2011a). Previous microarray
studies indicated that EphA2 and ephrin-A1 are also upre-
gulated by tumor necrosis factor-a (TNF-a) in keratinocytes
(Banno et al., 2004). Moreover, treating keratinocytes with
a combination of TNF-a and IL-17A captures additional
elements of the psoriatic transcriptome when compared with
individual cytokines (Chiricozzi et al., 2011). These studies
indicated that EphA2 and ephrin-A1 expression in keratino-
cytes may be regulated, at least in part, by growth factors and
cytokines elevated in psoriatic lesions.
As EphA2 mRNA and protein levels vary with differentia-
tion, we addressed the possibility that growth factors and
cytokines regulate receptor expression using neonatal foreskin
keratinocyte cultures maintained at two distinct stages of
differentiation: (1) relatively undifferentiated keratinocytes
maintained as subconfluent cultures in low (0.03 mM) Ca2þ
or (2) relatively differentiated keratinocytes maintained as
postconfluent cultures in high (1.2 mM) Ca2þ (Figure 1b). After
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Figure 1. Differentiation-dependent regulation of EphA receptor tyrosine
kinases (RTKs) in keratinocytes. (a) Quantitative reverse-transcriptase–PCR
(qRT–PCR) analysis of EphA (1/2/4) and ephrin-A (1/3) normalized to RPLP0
mRNA levels in keratinocytes isolated from a pool of neonatal foreskins (n¼ 3)
that were maintained in low (0.03 mM) Ca2þ , switched into high (1.2 mM)
Ca2þ for 3 days, or grown as human epidermal raft cultures for 9 days. Results
represent the mean (±SD) from three independent studies performed in
duplicate and normalized to raft cultures (*Po0.05). (b) Western blot analysis
of EphA subtypes (1/2/4), ephrin-A1, and epidermal structural proteins present
in the suprabasal layers (desmoglein 1, desmocollin 1, keratin 10, and loricrin)
in postconfluent primary cultures of human epidermal keratinocytes
maintained in low (0.03 mM) Ca2þ (day 0) or switched into high (1.2 mM) Ca2þ
for 1, 2, 3, or 6 days. E-cadherin was analyzed as a structural protein present
in keratinocytes at all stages of differentiation, whereas glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as a control for protein loading
and to normalize representative densitometry values for protein band
intensities relative to day 6 cultures. (c) Western blot analysis of keratinocytes
maintained in low Ca2þ or grown as human epidermal raft cultures at an
air–liquid interface for 9 days as compared with protein extracts prepared from
human neonatal foreskin. Eph, erythropoietin-producing hepatocellular;
NHEK, normal human epidermal keratinocyte.
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Figure 2. Increased EphA2 levels in the epidermis of psoriatic lesions. (a) A heat map of gene expression changes for the human EPH/EFN gene families as
analyzed by Affymetrix Human Genome U133 2.0 microarray using skin biopsies obtained from 64 normal (NN) or 58 psoriasis patients from nonlesional sites
(PN) or lesional plaques (PP). Eph, erythropoietin-producing hepatocellular. The mean fold changes (0.25 FC increments) obtained from these samples are
represented in the color-coded histogram (inset) where red indicates increased expression and green indicates decreased expression. False discovery rate (FDR)
was used to correct for multiple testing and indicates *Po0.05. (b) Quantitative reverse-transcriptase–PCR (qRT–PCR) analysis of EphA (1/2/4) and ephrin-A (1/3)
normalized to RPLP0 mRNA levels using 7 normal (NN; blue circles) and 10 paired PN (green squares) or PP (red triangles) samples. Values are expressed
as arbitrary units on the dot plot (mean horizontal bar; *Po0.05; **Po0.005). (c) Representative images of hematoxylin and eosin (H&E) staining and
immunohistochemistry (IHC) analysis of EphA2, ephrin-A1, and ephrin-A3 (n¼4) with higher-magnification insets. The dotted line highlights the basement
membrane zone. Scale bar¼ 50mm. (d) Mean fluorescence intensity (MFI) of EphA2 in the suprabasal layers and ephrin-A1 or ephrin-A3 in the basal layer. Error
bars (±SE) reflect the variation in pixel intensity among tissue sections (*Po0.05). (e) ELISA for EphA2 performed using protein lysates from five NN (blue circles),
three PN (green squares), or five PP (red triangles) skin biopsy samples. Values are expressed in a dot-plot format as protein concentration based on a standard
curve (mean horizontal bar; *Po0.05).
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24 hours of growth factor depletion, keratinocytes were treated
for 24 hours with EGF, IL-1a, TNF-a, or IL-17A (10 ng ml 1
each), alone or in combinations known to act in a synergistic
manner (Chiricozzi et al., 2011; Johnston et al., 2011a).
Accordingly, S100A7 mRNA and protein expression was
maximally upregulated by combined treatment with EGF
and IL-1a or TNF-a and IL-17A, particularly in the latter
condition under high Ca2þ conditions (Figure 3a–d). Although
the majority of these factors marginally increased EphA2
mRNA levels, this effect was most pronounced when differ-
entiated keratinocytes were treated in combination with EGF
and IL-1a or TNF-a and IL-17A (Figure 3a and c). In contrast,
ephrin-A1 mRNA transcripts were maximally upregulated by
TNF-a treatment alone in undifferentiated keratinocytes,
which is in line with its discovery as a TNFa-inducible gene
product in endothelial cells (Holzman et al., 1990). Postcon-
fluent adult keratinocyte cultures were also treated with
increasing doses of IL-1a, IFN-g, TNF-a, IL-17A, or IL-22 as
previously described (Gudjonsson et al., 2010b; Johnston
et al., 2011b). Compared with other epidermal EphA/ephrin-
A family members, EphA2 was the most significantly upre-
gulated receptor when adult keratinocytes were stimulated
with increasing concentrations of IL-1a, IFN-g, or TNF-a, but
not IL-17A or IL-22 (Supplementary Figure S3 online).
We next asked whether EphA2 protein expression was
altered by growth factor and cytokine treatment in undiffer-
entiated keratinocytes that express high levels of this receptor
or differentiated keratinocytes that express low levels of this
receptor. EphA2 protein was slightly increased by EGF, IL-1a,
TNF-a, and IL-17A under low-Ca2þ conditions (Figure 3b)
and more significantly elevated under Ca2þ -induced differ-
entiation conditions (Figure 3d), particularly when treated with
a combination of factors. The increase of EphA2 in response to
these cytokine combinations was associated with reduced
differentiation and increased S100A7 expression (Figure 3d).
EGF and cytokine exposure of human epidermal raft cultures
alters EphA2/ephrin-A1 levels
To assess cytokine-induced changes in the EphA2/ephrin-A1
signaling axis in a more physiologically relevant model,
we treated 3D epidermal raft cultures with EGF and IL-1a or
TNF-a and IL-17A for 72 hours. EphA2 mRNA and protein
levels were markedly upregulated after cytokine exposure
(Figure 4a and b) to a greater extent than that observed in
two-dimensional keratinocyte models (Figure 3). EphA2 nor-
mally exhibited a relatively diffuse distribution in the basal
layer and was concentrated at cell–cell contacts in the
suprabasal layers, whereas the addition of EGF and/or cyto-
kines enhanced receptor localization at the cell periphery in
basal keratinocytes (Figure 4c). We also noted a decrease in
ephrin-A1 mRNA and protein levels after cytokine exposure.
Finally, S100A7 mRNA transcripts were elevated to a greater
extent in TNF-a- and IL-17A-stimulated cultures, whereas protein
was detectable at low levels under control conditions and
markedly enhanced under both cytokine treatment regimens.
Consistent with a previous study (Johnston et al., 2011a),
EGF and IL-1a exposure grossly affected epidermal morphology
with disrupted cellular organization in the basal and spinous
layers, a paucity of keratohyalin granules, and an expansion of
the stratum corneum (Figure 4c; hematoxylin and eosin stain).
Accordingly, K10, desmoglein 1, and loricrin expression was
reduced in these raft cultures (Figure 4b). In contrast, the
morphological and differentiation-associated changes in TNF-
a- and IL-17A-stimulated raft cultures were relatively minor
compared with EGF and IL-1a exposure despite similar
induction in EphA2 expression, suggesting that the increase
in EphA2 by itself is not sufficient to impair differentiation. We
also tested the effects of a combination of factors (i.e., IL-1a,
TNF-a, and IL-6) previously used to model psoriasis in 3D
organotypic cultures (Tjabringa et al., 2008) and found that
this elevated EphA2 and S100A7 expression and impaired
differentiation (Supplementary Figure S4 online). Collectively,
these data show that a variety of cytokine insults associated
with psoriasis are capable of altering the EphA2/ephrin-A1
signaling axis in a raft model of human epidermis.
Ligand targeting of EphA2 in cytokine-exposed keratinocytes
enhances differentiation
To test the possibility that ephrins can limit the differentiation
defects induced by EGF and IL-1a, we first switched kerati-
nocytes from low to high Ca2þ in the presence of 1.0mg ml 1
EfnA1-Fc for 24 hours. Subsequently, we treated these kerati-
nocytes with EGF and IL-1a for an additional 24 hours. As
expected, cytokine exposure of Fc control cultures increased
EphA2 and inhibited differentiation (Figure 5a). Pretreatment
with the EfnA1-Fc peptide reduced the levels of EphA2 and
was capable of increasing desmoglein 1, desmocollin 1, K10,
and loricrin levels, but did not prevent the induction of
S100A7. Moreover, delivery of soluble ephrin ligand to epi-
dermal raft cultures limited differentiation defects associated
with EGF and IL-1a exposure (Figure 5b) and led to the
morphological restitution of the spinous, granular, and corni-
fied layers (Figure 5c). Finally, EfnA1-Fc treatment interfered
with the ability of EGF and IL-1a to aberrantly increase
proliferation in raft cultures (Figure 5d). We conclude from
these studies that ligand targeting of EphA2 can ameliorate the
proliferation and differentiation disrupting effects of these
particular inflammation-associated growth factors and cyto-
kines on keratinocytes.
DISCUSSION
Psoriasis is a complex inflammatory skin disease that not only
has a major immunological component but also involves
changes in epidermal architecture and keratinocyte differen-
tiation (Tschachler, 2007; Elder et al., 2010; Di Meglio et al.,
2011; Guttman-Yassky et al., 2011). Yet it remains largely
unclear why keratinocyte differentiation is abnormal, and
much remains to be revealed about the signaling pathways
that are dysregulated in psoriatic plaques. We found that EPH/
EFN gene expression is altered in psoriatic lesions and focused
on EphA2 owing to its most prominent upregulation in
plaques. Although abundant in primary keratinocytes along
with the related EphA1 and EphA4, EphA2 was uniquely
reduced during differentiation. Moreover, ephrin-A1 targeting
of EphA2 leads to its activation and downregulation to pro-
mote keratinocyte differentiation (Lin et al., 2010). In view of
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these observations, we propose a model for EphA2/ephrin-A1
actions in epidermal homeostasis, in which ephrin-A1 ligand
downregulates EphA2 to allow for normal differentiation.
In psoriatic lesions, we suspect that impaired keratinocyte
differentiation, reduced ephrin-A1 ligand expression, and the
integrated actions of growth factors and proinflammatory
cytokines work collectively to upregulate EphA2. Our analysis
of EphA2 in models of keratinocyte differentiation exposed to
cytokines suggests that it may be possible to compensate for a
lack of ligand using a recombinant ephrin peptide mimetic to
target this RTK and bolster the differentiation program.
Within psoriatic lesions, keratinocytes exhibit abnormal
differentiation but also increased proliferation (Leigh et al.,
1985; Weinstein et al., 1985; Tschachler, 2007). Interestingly,
the delivery of an EfnA1-Fc peptide limited keratinocyte
colony growth and suppressed proliferation-associated genes,
in line with the ability of these ligands to negatively regulate
proliferation in the mouse epidermis (Guo et al., 2006;
Genander et al., 2010; Walsh and Blumenberg, 2011).
Although EfnA1-Fc treatment had no significant effect on
keratinocyte proliferation in control raft cultures where
EphA2 levels are low, these soluble ligands were capable of
interfering with EGF- and IL-1a-induced hyperproliferation.
Consequently, ephrin-directed therapies for psoriasis may not
only bolster keratinocyte differentiation but also dampen
proliferation in lesional epidermis.
Alterations in the Eph/ephrin signaling axis in psoriasis are
consistent with their regulation during inflammation in other
organs. For example, EphA2 is rapidly increased in response to
lipopolysaccharide-induced inflammation in the rat lung and
liver, followed by a downregulation of EphA1 (Ivanov et al.,
2005). In contrast, ephrin-A1 is transiently downregulated and
subsequently increased along with ephrin-A3 at later stages.
Moreover, EphA2 and ephrin-A1 are coordinately induced
by proinflammatory cytokines (i.e., TNF-a and IL-1b) in
endothelial cells (Funk et al., 2012). Hence, alterations in
the EphA2/ephrin-A1 signaling axis likely occur in multiple
cellular compartments of the skin during inflammation and
may even have a role in normal wound healing where
proinflammatory cytokines and EGF ligands are increased
(Marikovsky et al., 1993; Barrientos et al., 2008).
A number of signaling pathways suppressed by ephrin-A1
may allow keratinocytes to resist the deleterious effects of
cytokines on differentiation. For example, Erk1/2–mitogen-
activated protein kinase signaling downstream of EGFR is
dampened to allow for differentiation and becomes elevated
in psoriatic lesions (Haase et al., 2001; Takahashi et al., 2002).
Ephrin-mediated inhibition of Erk1/2–mitogen-activated
protein kinase signaling in keratinocytes (Guo et al., 2006;
Lin et al., 2010) can potentially suppress abnormal signaling
elicited by EGFR. As EGFR–Erk1/2 signaling also increases
EPHA2 gene expression, EphA2 likely serves in a negative
feedback loop that dampens Erk1/2–mitogen-activated protein
kinase signaling after ephrin binding (Miao et al., 2001;
Macrae et al., 2005; Larsen et al., 2007). Microarray
analysis suggests that the EfnA1-Fc peptide can reduce the
expression of genes targeted by the NF-kB pathway, which is
an important mediator of skin inflammation (Chan et al.,
2006; Walsh and Blumenberg, 2011). S100A7, a target of
N-FkB regulation (Zaba et al., 2007; Chiricozzi et al., 2011),
was not reduced by the delivery of the EfnA1-Fc peptide.
However, it is possible that increasing the levels of native
ephrin-A1 in the epidermis can render keratinocytes resistant
to cytokine insults and possibly even limit their ability to
participate in an inflammatory cascade inherent in psoriasis.
MATERIALS AND METHODS
Study population
Subjects for gene expression analysis were enrolled using a protocol
approved by the University of Michigan institutional review board
(HUM00037994) as previously described (Gudjonsson et al., 2010a);
this study group includes 64 normal controls and 58 psoriasis patients
with at least one well-demarcated plaque covering 41% of the total
body surface area. For IHC studies, biopsies were obtained from four
additional subjects who provided written, informed patient consent to
the institutional review board-approved Northwestern University
Dermatology Tissue Repository. Patients had not received systemic
treatment for at least 2 weeks or topical treatment for at least 1 week
before the biopsy. This study was conducted in compliance with good
clinical practice and according to the Declaration of Helsinki Principles.
Microarrays
Microarray data and statistical analysis was performed using control
(NN) or paired nonlesional (PN) and lesional (PP) skin specimens
from psoriasis patients as previously described (Gudjonsson et al.,
2010a). Raw data have been deposited in the Gene Expression
Omnibus database and are available under the accession number
GSE13355. For each EPH/EFN gene, a representative probe set was
chosen as that which yielded the most significant result among the
three comparisons of interest (PP vs. NN, PP vs. PN, and PN vs. NN).
Heat maps for the changes in the Eph/ephrin family were generated
using the R statistical software package (http://www.r-project.org/).
Cell culture and retroviral gene expression
To help account for potential donor variability, most studies were
conducted using human neonatal keratinocytes isolated from a pool
(3–5 individuals) of foreskins and maintained in Medium 154
supplemented with human keratinocyte growth factor (M154þ
HKGS; Invitrogen/Cascade Biologics, Portland, OR) and 0.07 mM
calcium chloride (Ca2þ ). Subconfluent keratinocyte cultures were
switched into low (0.03 mM) Ca2þ to limit differentiation or seeded to
confluency and switched into high (1.2 mM) Ca2þ to induce differ-
entiation as previously described (Lin et al., 2010). Additional
cytokine stimulation experiments were performed using human
adult keratinocyte cultures established as described (Elder et al.,
1992) and maintained in M154þHKGS and 0.1 mM Ca2þ . For all
cytokine treatment studies, keratinocytes were starved of growth
factors for 24 hours before stimulation with the indicated combina-
tion and concentration of recombinant murine EGF (Chemicon,
Millipore, Billerica, MA), IL-1a (Peprotech, Rocky Hill, NY), IFN-g,
TNF-a, IL-6, IL-17A, IL-22 (R&D Systems, Minneapolis, MN), or 0.1%
BSA/phosphate-buffered saline (Sigma Aldrich, St Louis, MO) as a
vehicle control. For ligand-targeting experiments, keratinocytes were
incubated in the presence of 1.0mg ml 1 recombinant EfnA1-Fc
chimera (R&D Systems) or human Fc alone (Jackson Immuno-
Research Laboratories, West Grove, PA). The 3D organotypic raft
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models of human epidermis were established as previously described
(Getsios et al., 2009; Simpson et al., 2010).
To ectopically express ephrin-A ligands in keratinocytes, a full-
length human ephrin-A1 complementary DNA (cDNA) was obtained
from W Debinski (Wake Forest University Medical Center, Winston-
Salem, NC) (Wykosky et al., 2007; Kaplan et al., 2012) and a full-
length murine ephrin-A3 cDNA was obtained from Y Yamaguchi
(Burnham Institute for Medical Research, La Jolla, CA) (Irie et al.,
2008). These ephrin cDNAs were subcloned into the pLZRS-Linker
vector (Denning et al., 2002). Retroviral supernatants were generated to
transduce keratinocytes as previously described (Getsios et al., 2009).
Quantitative reverse-transcriptase–PCR
Total RNA was extracted using the RNeasy Mini kit (Qiagen,
Valencia, CA) and reverse transcribed (High-Capacity cDNA Tran-
scription kit; Applied Biosystems, Foster City, CA) as previously
described (Johnston et al., 2011a). Taqman primer sets for EphA1/2/
4, ephrin-A1/3, or S100A7 were purchased from Applied Biosystems
(see Supplementary Table S2 online). All values were normalized to
the expression of the housekeeping gene, ribosomal protein, large, P0
(RPLP0) (Minner and Poumay, 2009). A paired Student’s t-test was
used to compare nonlesional and lesional biopsies from psoriasis
patients. An unpaired t-test was used for all other comparisons, with
Po0.05 values considered significant.
Western blot analysis and ELISA
Total protein was extracted using 8 M urea sample buffer as previo-
usly described (Lin et al., 2010). Immunoblots were probed using
antibodies directed against the following proteins: EphA2 (D7;
Millipore), EphA1 (AF638; R&D Systems), EphA4 (S-20-Santa Cruz
Biotechnology, Grand Island, NY), ephrin-A1 (V-18; Santa Cruz
Biotechnology), ephrin-A3 (K19; Santa Cruz Biotechnology, Santa
Cruz, CA), K10 (RBK10; gift from J Serge, National Institutes of Health,
Bethesda, MD), desmoglein 1 (27B2; Zymed, Life Sciences, Grand
Island, NY), desmocollin 1 (U100; Progen, Queensland, Australia),
loricrin (PRB-145P; Covance, Princeton, NJ), S100A7 (HID5; Imgenex,
San Diego, CA), E-cadherin (HECD-1; Invitrogen, Life Sciences), and
GAPDH (ab9485; Abcam, Cambridge, MA). Relative band intensities for
proteins were normalized to GAPDH and calculated using the ImageJ
software (National Institutes of Health, Bethesda, MD).
RIPA-soluble protein extracts were prepared from skin biopsies of
healthy individuals (NN; n¼ 5) and psoriasis patients (PN, n¼ 3; PP,
n¼ 5) as previously described (Gudjonsson et al., 2010b) and
analyzed by an ELISA for EphA2 according to the manufacturer’s
instructions (R&D Systems).
Histology, IHC, and BrdU incorporation studies
For histology, formalin-fixed, paraffin-embedded tissue sections were
stained with hematoxylin and eosin. For IHC, optimal cutting
temperature compound–embedded frozen tissue sections were fixed
with 4% paraformaldehyde and immunostained as previously des-
cribed (Kaplan et al., 2012) using the following antibodies: EphA2
(AF3035; R&D Systems), ephrin-A1 (V18), ephrin-A3 (H-90; Santa
Cruz Biotechnology), K10 (LH2; Chemicon), and S100A7 (HID5;
Imgenex). IHC imaging was performed using an epifluorescence Zeiss
Axiovision Z1 microscope containing an Apotome slide module and
a high-resolution AxioCam MRm digital camera. Image analysis was
performed with the Zeiss AxioVision software (Thornwood, NY).
The ImageJ software (National Institutes of Health, Bethesda, MD)
was used to calculate the pixel intensity of ephrin-A1, ephrin-A3,
or EphA2 from the basal or suprabasal layers of the epidermis,
respectively (n¼ 4); these values were normalized for total area to
calculate the mean fluorescence intensity.
To assess proliferation following ephrin treatment in the 3D model
of human epidermis, raft cultures were incubated in the presence of
10mM BrdU (Sigma, St Louis, MO) for 60 minutes before formalin
fixation and immunostaining for this nucleoside as previously
described (Getsios et al., 2009). The total number of BrdU-positive
cells divided by the total number of basal cells was calculated from
multiple (410) image frames, with 4400 total cells counted from
each experiment (n¼ 3).
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